Chemours Co. (CC)
Chemours: The Current Trajectory Is Not Reflective Of The Upside
Chemours is rated 'BUY' with a $20 price target and $30 fair value, reflecting significant undervaluation and recovery potential. CC's investment thesis centers on operating leverage, balance sheet repair, and recovery in non-thermal segments, with normalized EPS targeted at $2.5/share. Despite current elevated leverage (4.4x) and declining earnings, CC's debt reduction and EBITDA improvement could drive re-rating and substantial upside by 2027-2028E.
The Dividend Screener Says High Yield. But These Chemical Stocks Tell a Different Story
Chemical stocks are flashing some of the highest dividend yields in the sector right now, but the number your screener shows and the check you will actually receive are not the same thing, and the gap between them hides a
Chemours (CC) Up 7.5% Since Last Earnings Report: Can It Continue?
Chemours (CC) reported earnings 30 days ago. What's next for the stock?
Chemours Expands Low-GWP Refrigerant Portfolio for Data Centers
CC expands its low-GWP Opteon refrigerant portfolio to meet rising cooling needs from AI-driven data centers and support decarbonization goals.
Chemours' Q2 Earnings & Revenues Lag Estimates on Lower Volumes
CC's Q2 loss narrows, but lower volumes and sales weigh on results as it outlines a cautious Q3 outlook.
Leading Women-Run Companies Shaping the Future of Business
CNC, DAR, GD, FCEL and CC stocks show how women-led companies are redefining growth with discipline, agility and results.
Chemours: Close To A 'Perfect' Rotation, With A 'Buy' In Q2 2026 (Rating Upgrade)
Chemours is upgraded to 'BUY' with a $20 PT and $30 fair value, reflecting renewed upside after recent volatility. CC's recent rally was driven by sentiment, not fundamentals, but the company now shows improving liquidity, debt reduction, and solid EBITDA guidance. Risks remain from regulatory liabilities and elevated leverage, but CC's divestment plan and Opteon growth support a high-conviction turnaround thesis.
The Chemours Company (CC) Q2 2026 Earnings Call Transcript
The Chemours Company (CC) Q2 2026 Earnings Call Transcript
Chemours Q2 Earnings Call Highlights
Chemours NYSE: CC said its second-quarter results reflected pricing gains, operational improvements and continued execution under its Pathway to Thrive strategy, while softer residential air-conditioning aftermarket demand weighed on sales in its Thermal & Specialized Solutions business.
Compared to Estimates, Chemours (CC) Q2 Earnings: A Look at Key Metrics
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Misses Q2 Earnings and Revenue Estimates
Chemours (CC) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.58 per share a year ago.
Do Options Traders Know Something About Chemours Stock We Don't?
Investors need to pay close attention to CC stock based on the movements in the options market lately.
